India · Delayed Price · Currency is INR Syngene International Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw 3% revenue growth, with Q4 rebounding 13% sequentially despite Librela headwinds. FY 2027 is expected to be flat as Librela impact fades, with margins guided in the mid-20s and growth anticipated from FY 2028 as new capabilities and contracts mature.
-
Q3 revenue declined 3% year-on-year due to a single large molecule product impact, while underlying research and CDMO businesses showed steady growth. Full-year revenue is now expected to decline 3%-5%, with the product headwind persisting into future quarters.
-
Q2 FY26 revenue grew 2% YoY to INR 911 crore, with research services outpacing CDMO, but EBITDA and PAT declined due to inventory correction and higher costs. The company maintained full-year guidance, expanded clinical trial and manufacturing capabilities, and expects stronger H2 performance.
-
Q1 FY26 delivered 11% revenue growth and 21% EBITDA growth, led by research services and operational milestones. Full-year guidance is maintained, with inventory adjustments in biologics expected to impact growth in coming quarters.
Fiscal Year 2025
-
India's clinical research market is rapidly expanding, driven by patient diversity, regulatory improvements, and cost advantages. Syngene has scaled its clinical research capabilities, offering integrated, end-to-end services and leveraging advanced technologies, with strong profitability and no major capacity constraints. A recent global trial win highlights its growing presence.
-
Q4 and FY 2025 saw resilient revenue growth, margin stability, and strategic U.S. biologics facility acquisition. FY 2026 guidance points to early-teens underlying growth, with reported growth tempered by inventory normalization and margin moderation due to new facility ramp-up.
-
Q3 marked a return to growth with 11% revenue increase and 23% higher operating EBITDA, driven by strong performance in Discovery Services and CDMO, especially biologics. Full-year guidance points to single-digit revenue growth and flat EBITDA, with continued investment in capacity and digital initiatives.
-
Q2 FY2025 saw flat YoY performance but 13% sequential revenue growth, with strong client interest in discovery and biologics services. Margin recovery and growth are expected in H2, with full-year revenue likely at the lower end of guidance.
-
Revenue and profit declined year-over-year in Q1 FY25, but leading indicators and client activity point to improved momentum in H2. Full-year guidance is unchanged, with EBITDA margin expected in the high 20s and PAT growth in single digits.